EMA Publishes Guidance on Preventing Medicine Shortages
The European Medicines Agency guidance highlights key principles and examples of good practices to prevent and manage shortages of human medicines.
The European Medicines Agency (EMA) released guidance detailing guidelines for patient and healthcare professional organizations on the prevention and management of shortages of medicines for human use on July 15, 2022. Identifying shortages and reduced availability as an increasing issue that has been amplified by the COVID-19 pandemic. The guidance seeks to present key recommendations for these situations.
Recommendations have been prepared based on consultations with member organizations of the EMA Patients’ and Consumers’ Working Party and Healthcare Professionals’ Working Party.Many of these recommendations draw on existing practices and initiatives in individual European Union member states where the suggested practices have been implemented, often in isolation.
Some key recommendations from the guidance suggest that relevant organizations should:
- Develop observatories in collaboration with national authorities to collect and analyze information from patients and healthcare professionals on shortages and their early signs;
- Work with national authorities on criteria and ways to develop registries of essential and critical medicines;
- Set up campaigns across the EU to raise awareness of shortages, where to find information on ongoing shortages, risks of stockpiling, and safe use of alternative medicines.
The full guidance can be read here.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
